

# The Current and Future Role of Oncologic Immunotherapies in the Management of Genitourinary Cancers

## CME INFORMATION

### TARGET AUDIENCE

This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

### OVERVIEW OF ACTIVITY

The past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. Although they may be diverse in terms of their biology and current clinical management, genitourinary (GU) cancers — prostate cancer, renal cell carcinoma (RCC), bladder cancer, et cetera — are unified in their potential as fertile ground for immunologic therapy and research and have been at the forefront of both past and current efforts in this regard. Not surprisingly, with the many exciting advances rapidly occurring both within the field of GU tumors and elsewhere, a number of vexing questions and clinical challenges are emerging simultaneously.

These video proceedings from a CME symposium held during the 2015 Genitourinary Cancers Symposium feature discussions with leading investigators in the management of prostate, renal and bladder cancer regarding actual patient cases and related clinical research findings. By providing information on important immunotherapeutic developments, this activity will assist medical and radiation oncologists, urologists and other healthcare professionals to address existing management uncertainties and determine the current role and future potential of immunotherapeutic interventions in patients with common GU cancers.

### LEARNING OBJECTIVES

- Develop a basic understanding of the human immune response, and identify the underlying mechanisms by which various tumor types evade this process to proliferate and grow.
- Analyze the biologic basis for various immunotherapeutic strategies designed to boost an individual's immune response to combat cancer.

- Effectively apply evidence-based research findings to appropriately integrate available immunotherapeutics into the management of advanced prostate cancer and RCC.
- Compare and contrast the mechanisms of action, efficacy and safety/toxicity of approved and investigational immunotherapies for the treatment of prostate cancer, RCC, bladder cancer and other GU tumors to determine the current and/or potential utility of each in clinical practice.
- Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies in patients with metastatic RCC and bladder cancer.
- Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics in order to offer supportive management strategies.
- Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches, and counsel appropriately selected patients with GU cancers about availability and participation.

### ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at [ResearchToPractice.com/GUCancers15/Immunotherapy/CME](http://ResearchToPractice.com/GUCancers15/Immunotherapy/CME).

### CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or

apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Charles G Drake, MD, PhD**

Co-Director  
Multi-D Prostate Cancer Clinic  
Associate Professor  
Oncology, Urology and Immunology  
Johns Hopkins Sidney Kimmel Cancer Center  
Baltimore, Maryland

**Consulting Agreements:** Amplimmune Inc, Bristol-Myers Squibb Company, Compugen, Dendreon Corporation, Eisai Inc, Genentech BioOncology, ImmuneXcite Inc, ImmuNext Inc, Novartis Pharmaceuticals Corporation, Potenza Therapeutics, Roche Laboratories Inc, Sanofi; **Patents:** Amplimmune Inc, Bristol-Myers Squibb Company, Potenza Therapeutics; **Stock Ownership:** Compugen, ImmuneXcite Inc, ImmuNext Inc.

**David F McDermott, MD**

Associate Professor of Medicine  
Harvard Medical School  
Director, Biologic Therapy and Cutaneous Oncology Programs  
Beth Israel Deaconess Medical Center  
Leader, Kidney Cancer Program  
Dana-Farber Harvard Cancer Center  
Boston, Massachusetts

**Advisory Committee:** Pfizer Inc; **Consulting Agreements:** Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Roche Laboratories Inc; **Contracted Research:** Novartis Pharmaceuticals Corporation.

**Daniel P Petrylak, MD**

Professor of Medicine  
Director, Prostate and GU Medical Oncology  
Co-Director  
Signal Transduction Program  
Yale Cancer Center  
New Haven, Connecticut

**Consulting Agreements:** Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, Pfizer Inc, Sanofi, Takeda Oncology; **Contracted Research:** Celgene Corporation, Sanofi, Takeda Oncology; **Grant Support:** Dendreon Corporation, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc.

**David I Quinn, MBBS, PhD**

Medical Director, Norris Cancer Hospital and Clinics  
Head, GU Cancer Section  
Division of Cancer Medicine and Blood Diseases  
USC/Norris Comprehensive Cancer Center  
Los Angeles, California

**Advisory Committee:** Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Biotech Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; **Consulting Agreements:** Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Biotech Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; **Other Remunerated Activities:** Medivation Inc.

**Nicholas J Vogelzang, MD**

Executive Medical Director  
US Oncology Research  
Associate Chair, Genitourinary and Developmental Therapeutics Programs  
Comprehensive Cancer Centers of Nevada  
Las Vegas, Nevada

**Consulting Agreements:** Amgen Inc, Aveo Pharmaceuticals, BIND Biosciences Inc, Janssen Biotech Inc; **Contracted Research:** GlaxoSmithKline, Pfizer Inc; **Honoraria:** AbbVie Inc, Bavarian Nordic, DAVA Oncology, Endocyte Inc, Mannkind Corporation, UpToDate Inc; **Paid Research:** Endocyte Inc, Exelixis Inc, GlaxoSmithKline, PAREXEL International Corporation, Progenics Pharmaceuticals Inc, US Oncology Inc, Viamet Pharmaceuticals Inc; **Paid Travel:** Bayer HealthCare Pharmaceuticals, Celgene Corporation, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, US Oncology Inc; **Speakers Bureau:** Bayer HealthCare Pharmaceuticals, Caris Life Sciences Ltd, Dendreon Corporation, GlaxoSmithKline, Medivation Inc, Sanofi, Takeda Oncology; **Stock Ownership:** Caris Life Sciences Ltd.

**MODERATOR** — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

**RESEARCH TO PRACTICE STAFF AND EXTERNAL**

**REVIEWERS** — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

*This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.*

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Genentech BioOncology and Prometheus Laboratories Inc.

**Hardware/Software Requirements:**

A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more  
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later  
Adobe Flash Player 10.2 plug-in or later  
Adobe Acrobat Reader  
(Optional) Sound card and speakers for audio

**Last review date:** July 2015

**Expiration date:** July 2016

## SELECT PUBLICATIONS

### David F McDermott, MD

Andersen MH et al. **Cytotoxic T cells.** *J Invest Dermatol* 2006;126(1):32-41.

Boudreau JE et al. **Engineering dendritic cells to enhance cancer immunotherapy.** *Mol Ther* 2011;19(5):841-53.

Callea M et al. **PD-L1 expression in primary clear cell renal cell carcinomas and their metastases.** *Proc ASCO* 2014;[Abstract 4585](#).

Drake CG et al. **Survival, safety, and response duration results of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma: Long-term patient follow-up.** *Proc ASCO* 2013;[Abstract 4514](#).

Hammers HJ et al. **Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma.** *Proc ASCO* 2014;[Abstract 4504](#).

Heemskerk B et al. **The cancer antigenome.** *EMBO J* 2013;32(2):194-203.

Hodi FS et al. **Improved survival with ipilimumab in patients with metastatic melanoma.** *N Engl J Med* 2010;363(8):711-23.

Hoos A. **Evolution of end points for cancer immunotherapy trials.** *Ann Oncol* 2012;23 (Suppl 8):viii47-52.

Janeway CA, Travers P, Walport M, Shlomchik M, eds. **Immunobiology: The Immune System in Health and Disease.** 6<sup>th</sup> ed. New York, NY: Garland Science; 2004.

Jilaveanu LB et al. **PD-L1 expression in clear cell renal cell carcinoma: An analysis of nephrectomy and sites of metastases.** *J Cancer* 2014;5(3):166-72.

Keir ME et al. **PD-1 and its ligands in tolerance and immunity.** *Annu Rev Immunol* 2008;26:677-704.

Lawrence MS et al. **Mutational heterogeneity in cancer and the search for new cancer-associated genes.** *Nature* 2013;499(7457):214-8.

Mellman I et al. **Cancer immunotherapy comes of age.** *Nature* 2011;480(7378):480-9.

Motzer RJ et al. **Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial.** *J Clin Oncol* 2014;[Epub ahead of print].

Pardoll DM. **The blockade of immune checkpoints in cancer immunotherapy.** *Nat Rev Cancer* 2012;12(4):252-64.

Ribas A et al. **New challenges in endpoints for drug development in advanced melanoma.** *Clin Cancer Res* 2012;18(2):336-41.

Ribas A et al. **Do we need a different set of response assessment criteria for tumor immunotherapy?** *Clin Cancer Res* 2009;15(23):7116-8.

Seiwert T et al. **A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer.** *Proc ASCO* 2014;[Abstract 6011](#).

Topalian SL et al. **Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.** *N Engl J Med* 2012;366(26):2443-54.

Vanneman M, Dranoff G. **Combining immunotherapy and targeted therapies in cancer treatment.** *Nat Rev Cancer* 2012;12(4):237-51.

Whiteside TL et al. **Immune responses to cancer: Are they potential biomarkers of prognosis?** *Front Oncol* 2013;3:107.

Wolchok JD et al. **Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria.** *Clin Cancer Res* 2009;15(23):7412-20.

### Daniel P Petrylak, MD

Akbari O et al. **PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.** *Mucosal Immunol* 2010;3(1):81-91.

Garon EB et al. **Safety and clinical activity of MK-3475 in previously treated patients with non-small cell lung cancer.** *Proc ASCO* 2014;[Abstract 8020](#).

Herbst RS et al. **A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.** *Proc ASCO* 2013;[Abstract 3000](#).

**KEYNOTE-012: A phase Ib multi-cohort study of MK-3475 in subjects with advanced solid tumors.** [NCT01848834](#)

Matsumoto K et al. **B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma.** *Biochem Biophys Res Commun* 2008;365(1):170-5.

Plimack ER et al. **A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients with advanced urothelial tract cancer.** *Proc ESMO* 2014;[Abstract LBA23](#).

Powles T et al. **MPDL3280A treatment leads to clinical activity in metastatic bladder cancer.** *Nature* 2014;515(7528):558-62.

Ribas A et al. **Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients with melanoma.** *Proc ASCO* 2014;[Abstract 9000](#).

Rizvi NA et al. **Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer.** *Proc ASCO* 2014;[Abstract 8007](#).

Seiwert TY et al. **A phase 1b study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer.** *Proc ASCO* 2014;[Abstract 6011](#).

Soria JC et al. **Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer: Additional analyses from a clinical study of the engineered antibody MPDL3280A.** *Proc ESMO* 2013;[Abstract 3408](#).

#### **Charles G Drake, MD, PhD**

**A randomized, open-label, phase 2 trial examining the sequencing of sipuleucel-T and androgen deprivation therapy in men with non-metastatic prostate cancer and a rising serum prostate specific antigen after primary therapy.** [NCT01431391](#)

Antonarakis ES et al. **Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer.** *Proc Genitourinary Cancers Symposium* 2015;[Abstract 171](#).

Beer TM et al. **Characterization of immune-related adverse events in a phase 3 trial of ipilimumab versus placebo in post-docetaxel mCRPC.** *Proc Genitourinary Cancers Symposium* 2014;[Abstract 52](#).

**CA184-043: A randomized, double-blind, phase 3 trial comparing ipilimumab versus placebo following radiotherapy in subjects with castration resistant prostate cancer that have received prior treatment with docetaxel.** [NCT00861614](#)

Drake CG et al. **Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer.** *Proc Genitourinary Cancers Symposium* 2014;[Abstract 88](#).

Drake CG. **Prostate cancer as a model for tumour immunotherapy.** *Nat Rev Immunol* 2010;10(8):580-93.

Gerritsen WR et al. **CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival in patients with post-docetaxel castration-resistant prostate cancer and bone metastases treated with ipilimumab vs placebo, each following single-dose radiotherapy.** *Proc European Multidisciplinary Cancer Congress* 2013;[Abstract 2850](#).

GuhaThakurta D et al. **Humoral immune response against non-targeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome.** *Clin Cancer Res* 2015;[Epub ahead of print].

**Prospect: A randomized, double-blind, phase 3 efficacy trial of PROSTVAC-V/F +/- GM-CSF in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.** [NCT01322490](#)

Quinn DI et al. **A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer.** *Proc ASCO* 2014;[Abstract 16071](#).

**STRIDE: A randomized, open-label, phase 2 study of sipuleucel-T with concurrent versus sequential administration of enzalutamide in men with metastatic castrate-resistant prostate cancer.** [NCT01981122](#)

#### **David I Quinn, MBBS, PhD**

**A randomized, blinded, phase 2 dose-ranging study of BMS-936558 (MDX-1106) in subjects with progressive, advanced/metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy.** [NCT01354431](#)

**A randomized, open-label, phase 3 study of nivolumab (BMS-936558) versus everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy.** [NCT01668784](#)

**Axitinib (Ag-013736) as second line therapy for metastatic renal cell cancer: Axis trial.** [NCT00678392](#)

**CheckMate 214: A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma.** [NCT02231749](#)

Escudier B et al. **Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial.** *Lancet* 2007;370(9605):2103-11.

Escudier B et al. **Sorafenib in advanced clear-cell renal-cell carcinoma.** *N Engl J Med* 2007;356(2):125-34.

Fyfe G et al. **Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.** *J Clin Oncol* 1995;13(3):688-96.

Hamanishi J et al. **Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.** *Proc Natl Acad Sci USA* 2007;104(9):3360-5.

Hammers HJ et al. **Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma.** *Proc ASCO* 2014;**Abstract 4504.**

Hudes G et al. **Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.** *N Engl J Med* 2007;356(22):2271-81.

McDermott DF et al. **Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma.** *Proc ASCO* 2012;30:**Abstract 4505.**

McDermott DF et al. **The high-dose aldesleukin (HD IL-2) Select trial in patients with metastatic renal cell carcinoma: Preliminary assessment of clinical benefit.** *Proc Genitourinary Cancers Symposium* 2010;**Abstract 321.**

Morse M et al. **High-dose IL-2 for metastatic renal cell carcinoma in the targeted therapy era: Extension of OS benefits beyond complete response and partial response.** *Proc ASCO* 2014;**Abstract 4523.**

Motzer RJ et al. **Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.** *Proc ASCO* 2014;**Abstract 5009.**

Motzer RJ et al. **Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial.** *J Clin Oncol* 2014;[Epub ahead of print].

Motzer RJ et al. **Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial.** *Lancet* 2008;372(9637):449-56.

Motzer RJ et al. **Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.** *N Engl J Med* 2007;356(2):115-24.

Rini BI et al. **Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma: Results of phase III AXIS trial.** *Proc ASCO* 2011;**Abstract 4503.**

Rini BI et al. **Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.** *J Clin Oncol* 2008;26(33):5422-8.

Sternberg CN et al. **Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial.** *J Clin Oncol* 2010;28(6):1061-8.

Thompson RH et al. **Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.** *Cancer Res* 2006;66(7):3381-5.

#### **Nicholas J Vogelzang, MD**

Brahmer JR et al. **Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.** *N Engl J Med* 2012;366(26):2455-65.

Davies M. **New modalities of cancer treatment for NSCLC: Focus on immunotherapy.** *Cancer Manag Res* 2014;6:63-75.

Herbst RS et al. **Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.** *Nature* 2014;515(7528):563-7.

Inoue A et al. **Radiation pneumonitis in lung cancer patients: A retrospective study of risk factors and the long-term prognosis.** *Int J Radiat Oncol Biol Phys* 2001;49(3):649-55.

Topalian SL et al. **Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.** *N Engl J Med* 2012;366(26):2443-54.